Study Tests hERG IC10 for Drug QT Risk
Researchers propose a 10% hERG channel inhibition threshold as an alternative to the conventional IC50 approach for assessing drug-induced QT prolongation.
Updated on Nov. 4, 2026 in Heart Disease
Dr. William J. Crumb Jr. and Dr. Andrew G. Edwards published a study in the Journal of Pharmacological and Toxicological Methods evaluating whether a 10% hERG potassium channel inhibition metric (IC10) can predict QT safety better than the IC50 method. The work was announced in a press release dated November 4, 2026.
Why it matters
QT prolongation is a cardiac safety concern in drug development, and regulators rely on preclinical potassium channel data to screen for it. A more accurate predictive metric could help identify heart-rhythm risks earlier in the development process.
The study compares a 10% hERG potassium channel inhibition threshold (IC10) against the conventional IC50 metric for predicting QT prolongation. The source material does not report quantitative validation results, so the comparative accuracy of the two approaches remains to be detailed in the full paper.
The players
William J. Crumb Jr.
Crumb is President and CEO of Nova Research Laboratories, LLC and has conducted manual patch clamp studies supporting preclinical drug cardiac risk research.
Andrew G. Edwards
Edwards is Chief Research Scientist at Simula Research Laboratory in Oslo, Norway, and also serves as COO of Organos in Berkeley, California.
The details
The researchers combined experimental electrophysiology expertise with computational physiology expertise to examine whether an IC10-based metric could improve on the IC50-based approach for thorough QT safety assessment. Dr. Crumb has previously conducted manual patch clamp studies in support of preclinical drug cardiac risk research.
Timeline
November 4, 2026: Press release on the study issued via GlobeNewswire, datelined New Orleans.
Health Landscape
Preclinical cardiac safety screening has long relied on hERG potassium channel inhibition data to flag QT prolongation risk before human trials. This study tests whether shifting the benchmark from the conventional IC50 measure to a 10% inhibition threshold could refine that screening.
If a more accurate preclinical screen is adopted, drugs with potential heart-rhythm side effects could be identified earlier in development. Patients would be less likely to encounter unexpected QT-related risks from medications on the market.
The takeaway
Preclinical tests that better predict heart-rhythm risk can help catch dangerous drug effects before people take them. Readers following drug safety should watch for how regulators treat alternative metrics like IC10 in future guidance.
Further reading
For more on the conditions this cardiac safety research aims to protect against, explore Heart Disease.
